Sandoz is the generic division of Novartis and the acquisiton of Fougera will reside within this division it appears.  The two companies already service some of the same accounts.  BD

is buying specialty dermatology generics firm Fougera Pharmaceuticals for $1.525 billion in cash. The Swiss drug imagegiant says adding Fougera to its Sandoz generics business will transform the latter into the world’s biggest generic dermatology medicines operation, with estimated annual global sales approaching $620 million.

The addition of Fougera’s leading portfolio further strengthens Sandoz’ differentiated products strategy,” comments Jeff George, global head of Sandoz. “Fougera brings us valuable technical capabilities in the area of topical dermatology products, particularly in the development and manufacturing of semisolid forms such as creams and ointments.”


Post a Comment

Google Analytics Alternative